

Tissue engineered autologous grafting versus standard care in the treatment of diabetic foot ulcers

Submission date 24/06/2009	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 11/08/2009	Overall study status Completed	☐ Protocol
Last Edited 11/08/2009	Condition category Nutritional, Metabolic, Endocrine	☐ Statistical analysis plan
		☐ Results
		☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Doriana Senigaglia

Contact details

Via Ponte della Fabbrica 3/B
Abano Terme - Padova
Italy
35031

Additional identifiers

Protocol serial number

CT/240/248/98-03

Study information

Scientific Title

Evaluation of the efficacy and safety of autologous grafts of fibroblasts and keratinocytes grown on scaffolds composed of HYAFF 11, a derivative of hyaluronic acid, in the treatment of diabetic foot ulcers: a randomised, controlled, multicentre trial

Study objectives

The study compared the efficacy and adverse event profile of autologous tissue engineered grafts (Hyalograft 3D™ autograft and Laserskin® autograft) versus standard care (paraffin gauze) in the local treatment of diabetic foot ulcers.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics Committee of the Università Cattolica del Sacro Cuore - Facoltà di Medicina e Chirurgia (Agostino Gemelli) approved on the 22nd February 1999 (ref: Prot.Dg P37/C.E. [A. 48]). The study received the favourable opinion by the Ethic Committees of all the 7 centres involved. All other centres will seek ethics approval before recruiting participants.

Primary study design

Interventional

Study design

Randomised controlled multicentre clinical trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Diabetic foot ulcer

Interventions

The study protocol provided a first treatment phase with the grafting of Hyalograft 3D™ autograft (autologous graft of fibroblasts grown on a HYAFF scaffold) followed, a fortnight later, by the grafting of Laserskin® autograft (autologous graft of keratinocytes grown on a HYAFF scaffold). Single or double grafts of each products were allowed at the investigator's discretion.

The control group was treated with the paraffin gauze Jelonet on direct contact with the wound.

All the patients used an appropriate off-loading device (plantar ulcers) or therapeutic shoes (dorsal ulcers).

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Hyalograft 3D™ autograft, Laserskin® autograft

Primary outcome(s)

Rate of healing at 12 and 20 weeks (complete healing was defined as complete re-epithelialisation of the wound).

Key secondary outcome(s)

Evaluated at 12 weeks:

1. Mean healing time
2. Time to achieve 50% area reduction
3. Weekly percentage of ulcer area reduction

Registered during the entire course of the study; a specific analysis was performed at 12 weeks and at the 18 months follow-up:

4. Number and severity of adverse events

In order to enhance the quality of the observation, the tolerability of the treatment was observed during the treatment period and at the 18 months follow-up.

Completion date

17/01/2006

Eligibility**Key inclusion criteria**

1. Patient with diabetes type 1 or 2, with ulcer located on plantar or dorsal site, with an area greater than 2 cm²
2. Male or female greater than or equal to 18 years old
3. Non-fertile female or fertile females, who use oral contraceptives or intrauterine devices and with a negative pregnancy test
4. Ulcer with Wagner score 1 - 2
5. Patients with transcutaneous partial pressure of oxygen (TcPO₂) greater than or equal to 20 mmHg
6. Ulcers without tendency to heal for at least 1 month
7. Ankle branchial index greater than or equal to 0.5

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

1. Patients who did not give written informed consent
2. Patients with osteomyelitis
3. Ulcers with positive bacteriological swabs
4. Patients for whom the use of off-loading device is not recommended

5. Patients who have a re-vascularisation from less than 30 days
6. Patients with serious liver and/or renal insufficiency
7. Patients with malignant neoplasm or diseases with unfavourable prognosis
8. Patients in treatment with corticosteroids, immunosuppressants and/or cytostatic drugs
9. Pregnancy or suspected pregnancy
10. Participation on another clinical trial in foot ulcer treatment during the last two weeks

Only for patients assigned to the treatment group (tissue engineered autografts):

11. Patients who refuse to undergo, prior to study initiation, the following tests: 11.1. Hepatitis B surface antigens (HBsAg)
- 11.2. Hepatitis C virus (HCV)
- 11.3. Anti-human immunodeficiency virus 1 (Anti-HIV 1)
- 11.4. Anti-human immunodeficiency virus 2 (Anti-HIV 2)

Date of first enrolment

15/09/1999

Date of final enrolment

17/01/2006

Locations

Countries of recruitment

Italy

Study participating centre

Via Ponte della Fabbrica 3/B

Abano Terme - Padova

Italy

35031

Sponsor information

Organisation

Fidia Advanced Biopolymers Srl (Italy)

ROR

<https://ror.org/00dy5wm60>

Funder(s)

Funder type

Industry

Funder Name

Fidia Advanced Biopolymers Srl (Italy)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration